Drug Trial Radar · NCT06555640
A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
Last checked: Nov 19, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
79
Actual
Start
Aug 1, 2024
Primary completion
Jun 30, 2025
Study completion Aug 29, 2025
Sponsor
- Lead sponsor
- Zhejiang Doer Biologics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 17 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
DR10624 is an Fc fusion protein tri-agonist with balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR)/ fibroblast growth factor 21 receptor (FGF21R) agonizing activities. The objectives of the planned clinical investigation will be to evaluate the efficacy of DR10624 on fasting serum triglyceride (TG) levels after 12 weeks of treatment in subjects with severe hypertriglyceridemia (SHTG).
Conditions
- Severe Hypertriglyceridemia
Interventions
DR10624 InjectionDrug
Drug: DR10624 injection
PlaceboDrug
Drug: placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of fasting TGTime frame: From baseline to Week 12
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
Baoding No.1 Central Hospital
Baoding, China
The First Affiliated Hospital of Baotou Medical College
Baotou, China
Peking University First Hospital
Beijing, China
The First Affiliated Hospital of Bengbu Medical University
Bengbu, China
The First Hospital of Jilin University
Changchun, China
The Second Hospital of Jilin University
Changchun, China
Second Xiangya Hospital of Central South University
Changsha, China
Chifeng Municipal Hospital
Chifeng, China
Daqing People's Hospital
Daqing, China
The Affiliated Hospital of Hangzhou Normal University
Hangzhou, China
The Fourth Hospital of Harbin Medical University
Harbin, China
The First Affiliated Hospital of South China University
Hengyang, China
Inner Mongolia People's Hospital.
Hohhot, China
Huzhou Central Hospital
Huzhou, China
Lishui Municipal Central Hospital
Lishui, China
Luoyang Third Peoples Hospital
Luoyang, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, China
Meihekou Central Hospital
Meihekou, China
The Second Affiliated Hospital to Nanchang University
Nanchang, China
The Third Hospital of Nanchang
Nanchang, China
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, China
The Affiliated Hospital of Nantong University
Nantong, China
Nanyang Central Hospital
Nanyang, China
Panjin Liaoyou Baoshihua Hospital
Panjin, China
Pingxiang People's Hospital
Pingxiang, China
The People's Hospital of Liaoning Province
Shenyang, China
Shaanxi Provincial People's Hospital
Xi'an, China
The Third Affiliated Hospital of Xinjiang Medical University
Xinxiang, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, China
Yancheng First People's Hospital
Yancheng, China
Yixing People's Hospital
Yixing, China
Yiyang Central Hospital
Yiyang, China
Yueyang Central Hospital
Yueyang, China
Yuncheng Central Hospital
Yuncheng, China
Zibo Municipal Hospital
Zibo, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.